Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

Study Limitations:

• Not a head-to-head comparison of complement component 5 (C5) inhibitors
• Not placebo controlled
• Zilucoplan was administered at the end of the intravenous (IV) C5 inhibitor treatment cycle
• Before switching to zilucoplan, participants had clinically stable disease on an IV C5 inhibitor. In the RAISE clinical trial, patients starting zilucoplan had moderate-to-severe symptoms

The study included a selection bias for patients seeking alternatives to their current IV C5 inhibitor therapy. Reasons cited for switching included:

• Physical and logistic issues with IV infusions and challenges with venous access